References of "Krzesinski, Jean-Marie"
     in
Bookmark and Share    
Full Text
See detailKDIGO – prise en charge de l’hypertension artérielle en dialyse
Krzesinski, Jean-Marie ULg

Conference (2013, March 28)

1. A lower target may be chosen in CKD patients with proteinuria but after individualized risk-benefit assessment. The price to pay is a need for a higher number of antiHTA drugs and a risk of more ... [more ▼]

1. A lower target may be chosen in CKD patients with proteinuria but after individualized risk-benefit assessment. The price to pay is a need for a higher number of antiHTA drugs and a risk of more frequent side-effects. 2. Confirmation of a high BP level is necessary through out-of-the clinic BP measurement In CKD, ABPM offers night-time BP information useful for CV and renal risk evaluation. BP variability is a new point to be considered in the future. Proteinuria but also other specific risk factors (Phosphate, anemia, inflammation,..) should be integrated in the management of hypertension in CKD [less ▲]

Detailed reference viewed: 58 (2 ULg)
Full Text
See detailIntérêts et limites de la dialyse nocturne
Krzesinski, Jean-Marie ULg

Conference (2013, March 14)

Detailed reference viewed: 20 (1 ULg)
Full Text
Peer Reviewed
See detailCreatinine - or cystatin C - based equations to estimate glomerular filtration in the general population: impact on the epidemiology of chronic kidney disease
DELANAYE, Pierre ULg; CAVALIER, Etienne ULg; Moranne, Olivier et al

in BMC Nephrology (2013), 14

Chronic kidney disease (CKD) is a major issue in public health. Its prevalence has been calculated using estimation of glomerular filtration rate (GFR) by the creatinine-based equations developed in the ... [more ▼]

Chronic kidney disease (CKD) is a major issue in public health. Its prevalence has been calculated using estimation of glomerular filtration rate (GFR) by the creatinine-based equations developed in the Modified Diet in Renal Disease (MDRD) and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) study. Recently, new equations based either on cystatin C (CKD-EPI Cys) or both cystatin and creatinine (CKD-EPI mix) have been proposed by the CKD-EPI consortium. The aim of this study was to measure the difference in the prevalence of stage 3 CKD, defined as an estimated GFR less than 60 mL/min/1.73 m2, in a population using these four equations. METHODS: CKD screening was performed in the Province of Liege, Belgium. On a voluntary basis, people aged over 50 years have been screened. GFR was estimated by the four equations. Stage 3 CKD was defined as a GFR less than 60 mL/min/1.73 m2. RESULTS: The population screened consisted of 4189 people (47% were men, mean age 63 +/- 7y). Their mean serum creatinine and plasma cystatin C levels were 0.88 +/- 0.21 mg/dL and 0.85 +/- 0.17 mg/L, respectively. The prevalence of CKD in this population using the MDRD, the CKD-EPI, the CKD-EPI Cys and the CKD-EPI mix equations was 13%, 9.8%, 4.7% and 5%, respectively. The prevalence of CKD was significantly higher with the creatinine-based (MDRD and the CKD-EPI) equations compared to the new cystatin C-based equations. CONCLUSIONS: Prevalence of CKD varies strongly depending on the method used to estimate GFR. Such discrepancies are of importance and must be confirmed and explained by additional studies, notably by studies using GFR measured with a reference method [less ▲]

Detailed reference viewed: 66 (23 ULg)
Full Text
See detailStratification du risque cardiovasculaire selon la fonction
Krzesinski, Jean-Marie ULg

Conference (2013, March 09)

Detailed reference viewed: 18 (2 ULg)
Full Text
See detailHypertension artérielle résistante : place actuelle de la dénervation rénale dans sa prise en charge
Krzesinski, Jean-Marie ULg

Conference (2013, March 05)

HTA résistante touche 8% de la population hypertendue Nécessité d’une approche méthodique pour débusquer l’erreur dans la prise en charge Importance des médicaments interférant, du gain de poids et de ... [more ▼]

HTA résistante touche 8% de la population hypertendue Nécessité d’une approche méthodique pour débusquer l’erreur dans la prise en charge Importance des médicaments interférant, du gain de poids et de l’alimentation trop salée. Recherche d’un SAHOS Haute dose de diurétique et souvent association avec la spironolactone. Et si cela résiste? …dDénervation rénale? 1% des hypertendus traités! [less ▲]

Detailed reference viewed: 21 (0 ULg)
Full Text
Peer Reviewed
See detailParathormone and bone-specific alkaline phosphatase for the follow-up of bone turnover in hemodialysis patients : Is it so simple?
DELANAYE, Pierre ULg; DUBOIS, Bernard ULg; JOURET, François ULg et al

in Clinica Chimica Acta (2013), 417

Background: Chronic Kidney Disease (CKD) is associated with mineral and bone disorders (MBD). International guidelines suggest that levels of serum parathormone (PTH) or bone-specific alkaline phosphatase ... [more ▼]

Background: Chronic Kidney Disease (CKD) is associated with mineral and bone disorders (MBD). International guidelines suggest that levels of serum parathormone (PTH) or bone-specific alkaline phosphatase (b-ALP) can be used to evaluate MBD in dialysis patients. The evidence remains moderate and based on transversal studies. <br />Methods: We retrospectively investigated the variations of PTH (ΔPTH) and b-ALP (Δb-ALP) serum concentrations over a short (6-weeks) and a long (one-year) period in a monocentric hemodialysis population. The proportion of patients reaching the critical difference (CD) (50% for PTH and 25% for b-ALP) was calculated. <br />Results: Seventy-seven patientswere included. A significant correlation between PTHand b-ALP levelswas found at baseline (r=0.51). By contrast, no correlation was observed between ΔPTH and Δb-ALP over a 6-week interval (r=0.07). The CD for PTH and b-ALP was reached by 19 and 11 patients, respectively, with 2 patients showing consistent variations of both biomarkers. One year later, measurements were repeated in 48 survivors. <br />No correlation was found between ΔPTH and Δb-ALP (r=0.27). The CD for PTH or b-ALP was reached by 24 patients and 28 patients, respectively, with 6 patients (12.5%) showing opposite results for both biomarkers. <br />Conclusion: This study shows the lack of correlation between ΔPTH and Δb-ALP over time in patients under chronic hemodialysis. [less ▲]

Detailed reference viewed: 60 (18 ULg)
Peer Reviewed
See detailAnnual meeting of the SBN/BVN
BOUQUEGNEAU, Antoine ULg; DELANAYE, Pierre ULg; CAVALIER, Etienne ULg et al

Conference (2013)

Detailed reference viewed: 4 (2 ULg)
Peer Reviewed
See detailDeterminants of sclerostin concentration in hemodialysis patients.
DELANAYE, Pierre ULg; KRZESINSKI, Jean-Marie ULg; Warling, X et al

Poster (2013)

Detailed reference viewed: 6 (2 ULg)
Peer Reviewed
See detailDéterminant physiologique du NGAL sanguin et discordance entre NGAL sanguin et urinaire.
DELANAYE, Pierre ULg; Claisse, G; Mehdi, M et al

Poster (2013)

Detailed reference viewed: 12 (5 ULg)
Peer Reviewed
See detailDéterminant physiologique du NGAL sanguin et discordance entre NGAL sanguin et urinaire.
DELANAYE, Pierre ULg; Claisse, G; Mehdi, M et al

Poster (2013)

Detailed reference viewed: 15 (8 ULg)
Full Text
Peer Reviewed
See detailPeritoneal equilibration test with conventional ‘low pH/high glucose degradation product’ or with biocompatible ‘normal pH/low glucose degradation product’ dialysates: does it matter?
VAN OVERMEIRE, Lionel ULg; Goffin, Eric; Krzesinski, Jean-Marie ULg et al

in Nephrology Dialysis Transplantation (2013)

Abstract Background. The evaluation of the peritoneal transport characteristics is mandatory in peritoneal dialysis (PD) patients. This is usually performed in routine clinical practice with a peritoneal ... [more ▼]

Abstract Background. The evaluation of the peritoneal transport characteristics is mandatory in peritoneal dialysis (PD) patients. This is usually performed in routine clinical practice with a peritoneal equilibration test (PET) using conventional dialysates, with low pH and high glucose degradation product (GDP) concentrations. An increasing proportion of patients are now treated with biocompatible dialysates, i.e. with physiological pH and lower GDP concentrations. This questions the appropriateness to perform a PET with conventional solutions in those patients. The aim of our study is to compare the results of the PET using biocompatible and conventional dialysates, respectively. Methods. Nineteen stable PD patients (13 males, 6 females; mean age: 67.95 ± 2.36 years, mean body surface area: 1.83 ± 0.04 m2, dialysis vintage: 2.95 ± 0.19 years) were included, among which 10 were usually treated with biocompatible and 9 with conventional solutions. Two PETs were performed, within a 2-week interval, in each patient. PET sequence (conventional solution first or biocompatible solution first) was randomized in order to avoid ‘time bias’. Small (urea, creatinine and glucose), middle (beta-2-microglobulin) and large molecules’ (albumin and alpha-2-macroglobulin) dialysate/plasma (D/P) concentration ratios and clearances were measured during each PET. Ultrafiltration (UF) and sodium filtration were also recorded. Results of both tests were compared by the Wilcoxon paired test. Results. No statistical difference was found between both dialysates for small molecule transport rates or for sodium filtration and UF. However, a few patients were not similarly classified for small-solute transport characteristics within the PET categories. Beta-2-microglobulin and albumin D/P ratios at different time points of the PET were significantly higher with the biocompatible, when compared with the conventional, solutions: 0.10 ± 0.03 versus 0.08 ± 0.02 (P < 0.01) and 0.008 ± 0.003 versus 0.007 ± 0.003 (P = 0.01), respectively. A similar difference was also observed for beta-2-microglobulin that was higher with biocompatible dialysates (1.04 ± 0.32 versus 0.93 ± 0.32 mL/min, respectively). Conclusion. Peritoneal transport of water and small solutes is independent of the type of dialysate which is used. This is not the case for the transport of beta-2-microglobulin and albumin that is higher under biocompatible dialysates. Vascular tonus modification could potentially explain such differences. The PET should therefore always be carried out with the same dialysate to make longitudinal comparisons possible. [less ▲]

Detailed reference viewed: 64 (5 ULg)